Publications by authors named "S Barbus"
Article Synopsis
- Dupilumab is used for severe type 2 asthma, but patient characteristics in real-world settings are not fully understood, prompting this study to examine baseline data from the ProVENT study.
- In the analysis of 99 patients (59% females), key findings include a median age of 54 and a prevalence of adult-onset asthma (58%) and allergic phenotype (48%), with notable inflammatory markers such as FeNO and eosinophil counts.
- The study found diverse profiles among patients: 70% met at least one GINA criterion for airway inflammation, with 64% having T2-related comorbidities, indicating that eligibility for dupilumab treatment encompasses a range of clinical and biochemical
Objectives: The purpose of this study was to investigate the attainment of treatment goals according to the European Consensus Programme (ECP-TGs) from 2011 in patients with moderate to severe psoriasis (Pso) treated with the first conventional systemic therapy and to identify factors that might compromise the attainment of these treatment goals.
Methods: In a multicenter, prospective observational study, patients with moderate to severe Pso, defined as either body surface area (BSA) >10% or psoriasis area severity index (PASI) >10 and dermatology life quality index (DLQI) >10, received a conventional systemic therapy that could be modified at each follow-up visit over the course of 18 months. All subjects signed an informed consent form, were ≥18 years of age as well as systemic therapy naïve, and had regular study visits at months 3, 6, 9, 12, and 18 after baseline.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with an adverse impact on patients' quality of life (QoL). To quantify QoL impairment in patients in Germany suffering from HS and to identify the parameters associated with QoL impairment. A non-interventional, cross-sectional, mono-centric study with 500 HS patients.
View Article and Find Full Text PDFBackground: Hidradenitis suppurativa (HS) is a neglected chronic inflammatory disease with long delay in diagnosis. Besides pain, purulent discharge, and destruction of skin architecture, HS patients experience metabolic, musculoskeletal, and psychological disorders.
Objectives: To determine the delay in HS diagnosis and its consequences for patients and the healthcare system.
Hidradenitis suppurativa - prevalence analyses of German statutory health insurance data.
J Eur Acad Dermatol Venereol
January 2021